Results 361 to 370 of about 1,471,327 (421)
Children's agency in England's primary schools: A case for structured freedom
British Educational Research Journal, EarlyView.Abstract This paper examines how children's agency operates within primary education in England through an in‐depth qualitative study of three contrasting schools over two years. While children's right to participate in decisions affecting their education is increasingly recognised internationally, its practical implementation within formal education ...
Yana Manyukhina
wiley +1 more source
Biotechnology and Bioengineering, EarlyView.15R‐ and 15S‐lipoxygenases (15R‐ and 15S‐LOXs) were engineered into 18R‐ and 18S‐LOXs, respectively. Escherichia coli expressing these enzymes converted eicosapentaenoic acid into 18R‐ and 18S‐hydroxyeicosapentaenoic acids (18R‐ and 18S‐HEPEs), respectively.
Jin Lee +3 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The face of remission induction
British Journal of Haematology, 2019SummaryAcute myeloid leukaemia (AML) is a heterogeneous disease in which prognosis is determined by cytogenetic and molecular aberrations as well as patient‐related factors, including age, prior haematologic disorders, and comorbidities. Despite the diverse disease biology, the standard of care for remission induction therapy has changed very little ...
Shilpa Paul +2 more
openaire +4 more sources
Gut, 2022
Objective There are numerous biological therapies and small molecules licensed for luminal Crohn’s disease (CD), but these are often studied in placebo-controlled trials, meaning relative efficacy is uncertain. We examined this in a network meta-analysis.
B. Barberio +3 more
semanticscholar +1 more source
Objective There are numerous biological therapies and small molecules licensed for luminal Crohn’s disease (CD), but these are often studied in placebo-controlled trials, meaning relative efficacy is uncertain. We examined this in a network meta-analysis.
B. Barberio +3 more
semanticscholar +1 more source
Natalizumab for induction of remission in Crohn's disease
Cochrane Database of Systematic Reviews, 2006The pathogenesis of Crohn's disease involves migration of leukocytes into gut tissue and subsequent inflammation. Natalizumab (Tysabri(R), Elan Pharmaceuticals and Biogen Idec) a recombinant humanized IgG4 monoclonal antibody that blocks adhesion and subsequent migration of leukocytes into the gut by binding the alpha4 integrin is a member of a new ...
John Wd McDonald, John K MacDonald
openaire +4 more sources
Journal of Gastroenterology and Hepatology, 2019
Oral 5‐aminosalicylic acid (5‐ASA) is recommended for the therapy of mild to moderate intestinal Behçet's disease (BD). However, the induction remission efficacy and endoscopic outcomes of 5‐ASA are unknown. We investigated remission induction at 8 weeks,
Hiroto Kinoshita +18 more
semanticscholar +1 more source
Oral 5‐aminosalicylic acid (5‐ASA) is recommended for the therapy of mild to moderate intestinal Behçet's disease (BD). However, the induction remission efficacy and endoscopic outcomes of 5‐ASA are unknown. We investigated remission induction at 8 weeks,
Hiroto Kinoshita +18 more
semanticscholar +1 more source
Budesonide for induction of remission in Crohn's disease
Cochrane Database of Systematic Reviews, 2015Corticosteroids are commonly used for the induction of remission in Crohn's disease. However, traditional corticosteroids can cause significant adverse events. Budesonide is an alternative glucocorticoid with limited systemic bioavailability.The primary objective was to evaluate the efficacy and safety of oral budesonide for the induction of remission ...
Anthony Otley +8 more
openaire +3 more sources